Welcome to our dedicated page for Modular Med news (Ticker: MODD), a resource for investors and traders seeking the latest updates and insights on Modular Med stock.
Modular Medical, Inc. (Nasdaq: MODD) is a development-stage medical device company focused on insulin delivery technology for people with diabetes. Its news flow centers on the design and development of user-friendly, affordable patch pumps, regulatory milestones for its Pivot tubeless insulin delivery system, and capital markets activity related to funding its operations.
Company announcements frequently highlight progress on the Pivot insulin delivery system, which Modular Medical describes as a next-generation, tubeless, removable three milliliter patch pump aimed at adult "almost-pumpers" who have not adopted traditional insulin pumps. News items include updates on Institutional Review Board (IRB) approvals for in-house studies, feasibility and insulin-use trials under simulated real-world conditions, and the submission of a 510(k) premarket filing to the U.S. Food and Drug Administration. The company also reports that the Pivot insulin delivery system is not currently cleared for sale by the FDA.
Investors following MODD news will also see disclosures about manufacturing readiness, such as validation of the Pivot controller manufacturing line for human-use production and steps toward high-volume manufacturing. Additional coverage includes progress toward CE Mark certification under EU MDR 2017/745, including ISO 13485:2016 quality management audits, as the company prepares for potential international commercialization.
Financial and listing-related updates form another important part of Modular Medical’s news stream. The company issues press releases on public offerings of common stock and warrants, warrant exercises and inducement agreements, and Nasdaq notices regarding minimum bid price compliance and related extensions. For those tracking MODD, this news page provides a centralized view of regulatory, operational, and financing developments affecting the company’s insulin delivery technology business.
Modular Medical, Inc. (OTCQB: MODD) announced the formation of a multi-disciplinary Advisory Board to enhance its insulin delivery technology. This Board, composed of renowned health care professionals, will collaborate with leadership to boost development and commercialization efforts. CEO Paul DiPerna emphasized the Board's diverse expertise as vital for reflecting real-world patient care issues. The Board aims to address the accessibility and usability of insulin pumps, making them simpler and more affordable for diabetes patients.
Modular Medical, Inc. (OTCQB:MODD) announced the relocation to a new 7,300 square foot headquarters in San Diego, CA, enhancing R&D capabilities for insulin pump development. The facility features a clean-room manufacturing environment and environmentally controlled test labs, crucial for upcoming 510(k) submission and increased testing activity. With a current staff of 20 and plans to hire for key positions, Modular Medical aims to expand access to advanced diabetes technology for underserved markets. CEO Paul DiPerna emphasized the strategic timing of this move amidst ongoing technology validation.
Modular Medical, Inc. (OTCQB:MODD) has officially uplisted to the OTCQB Venture Market, aiming to enhance trading liquidity and market visibility. Following three years of development, the company plans to submit its product for FDA approval this year, with a commercial launch anticipated in 2022. CEO Paul DiPerna emphasizes the mission to provide accessible diabetes technology to underserved insulin-dependent patients. The OTCQB standards ensure financial transparency and compliance, supporting the company's growth in the competitive diabetes care market.